Health Catalyst’s first quarter results were shaped by ongoing efforts to streamline its operations and address challenges from its previous client migration strategy, with management highlighting that a rigid migration timeline led to client churn and revenue pressure. CEO Benjamin Albert noted, “Setting a rigid timeline for migration efforts over the last 2 years has created a churn dynamic.” Despite these headwinds, the company reported strong bookings and progress on cost-saving initiatives, which contributed to a positive market reaction.
Is now the time to buy HCAT? Find out in our full research report (it’s free for active Edge members).
Health Catalyst (HCAT) Q1 CY2026 Highlights:
- Revenue: $70.76 million vs analyst estimates of $69.19 million (10.9% year-on-year decline, 2.3% beat)
- Adjusted EPS: $0.02 vs analyst estimates of $0.01 (in line)
- Adjusted Operating Income: -$2.98 million vs analyst estimates of -$10.81 million (-4.2% margin, 72.4% beat)
- Revenue Guidance for the full year is $262.5 million at the midpoint, below analyst estimates of $278.9 million
- EBITDA guidance for the full year is $31.5 million at the midpoint, below analyst estimates of $34.2 million
- Operating Margin: -150%, down from -25.4% in the same quarter last year
- Billings: $84.21 million at quarter end, down 11.7% year on year
- Market Capitalization: $87.93 million
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Health Catalyst’s Q1 Earnings Call
- Stanislav Berenshteyn (Wells Fargo) asked about the shrinking services mix. CEO Benjamin Albert explained services will decline as a percentage of revenue, but value-added services like chart abstraction will remain, often enhanced by AI.
- Richard Close (Canaccord Genuity) questioned client hesitancy to migrate from DAS to Ignite. Albert clarified that clients derive significant value from DAS and that transitions require substantial effort, so the company is now meeting clients where they are, rather than imposing rigid migration timelines.
- Jeffrey Garro (Stephens) inquired about customer feedback on Ignite Intelligence and AI budgeting. Management reported strong early feedback, citing the unique value of its proprietary improvement data and positive reception to cost management AI applications.
- Jessica Tassan (Piper Sandler) sought details on customer counts and ARR by platform. Management declined to disclose logo counts but noted that application relationships are often retained even after data infrastructure churn, emphasizing that intelligence layers distinguish their offering from commoditized data platforms.
- Eden Conniff (Stifel) asked about the composition of anticipated churn and bookings conversion. CFO Jason Alger confirmed churn is primarily from the data infrastructure side and stated bookings typically convert to revenue within three to six months, depending on the deployment.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) the pace and effectiveness of Project NEXUS restructuring and cost savings, (2) progress in stabilizing revenue as the migration-related churn is absorbed, and (3) adoption and monetization of new AI-powered analytics solutions. The ability to convert strong bookings into recurring revenue and improve technology segment margins will also be key milestones to watch.
Health Catalyst currently trades at $1.19, down from $1.38 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
